title: When the FRAX(®) test is applied to controlled clinical trials.
abstract: FRAX(®) is a computer-based algorithm developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases in Sheffield (UK). This algorithm calculates fracture probability from easily obtained clinical risk factors in men and women: age, sex, body mass index and dichotomized variables comprising prior fragility fracture, parental history of hip fracture, current tobacco smoking, use of long-term oral glucocorticoid, rheumatoid arthritis, other causes of secondary osteoporosis and high alcohol consumption (femoral neck bone mineral density can be optionally input to enhance fracture risk prediction). The output of FRAX(®) is the 10-year probability of a major osteoporotic fracture (hip, clinical spine, humerus or wrist fracture) and the 10-year probability of hip fracture.Recently various Authors have re-evaluated the effectiveness of drugs approved for postmenopausal osteoporosis to test whether they are more effective in women with higher FRAX(®) probabilities.
authors.affiliation: School of Medicine, Department of Internal Medicine, University of Catania, Italy.
authors.forename: Carmelo Erio
authors.initials: CE
authors.lastname: Fiore
authors.forename: Agostino
authors.initials: A
authors.lastname: Gaudio
keywords: FRAX®; alendronate; bazedoxifene; clodronate; denosumab; raloxifene; strontium ranelate